Miraculins Offers up to $470K in Placement | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) - Canadian diagnostics developer Miraculins aims to gain up to C$500,500 ($469,200) in gross proceeds through a private placement of as many as 7,150,000 units priced at C$.07 per unit.

The firm, which trades on the TSX Venture Exchange, said on Tuesday that it plans to use the proceeds from the placement for research and development and for corporate working capital.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.